Jessamine Victoria, Mehndiratta Samir, De Rubis Gabriele, Paudel Keshav Raj, Shetty Saritha, Suares Divya, Chellappan Dinesh Kumar, Oliver Brian G, Hansbro Phillip M, Dua Kamal
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia.
Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Heliyon. 2024 Feb 1;10(3):e25393. doi: 10.1016/j.heliyon.2024.e25393. eCollection 2024 Feb 15.
Chronic Obstructive Pulmonary Disease (COPD) is a dilapidating condition which is characterized by inflammation, an excess in free radical generation and airway obstruction. Currently, the drugs commercially available for the management of COPD pose several limitations such as systemic adverse effects, including bone density loss and an increased risk of developing pneumonia. Moreover, another limitation includes the need for regular and frequent dosing regimens; which can affect the adherence to the therapy. Furthermore, these current treatments provide symptomatic relief; however, they cannot stop the progression of COPD. Comparatively, nanoparticles (NPs) provide great therapeutic potential to treat COPD due to their high specificity, biocompatibility, and higher bioavailability. Furthermore, the NP-based drug delivery systems involve less frequent dosing requirements and in smaller doses which assist in minimizing side effects. In this review, the benefits and limitations of conventional therapies are explored, while providing an in-depth insight on advanced applications of NP-based systems in the treatment of COPD.
慢性阻塞性肺疾病（COPD）是一种逐渐恶化的疾病，其特征为炎症、自由基生成过多和气道阻塞。目前，用于治疗COPD的市售药物存在若干局限性，如全身不良反应，包括骨密度降低和患肺炎风险增加。此外，另一个局限性是需要定期频繁给药；这可能会影响对治疗的依从性。此外，这些现有治疗方法只能缓解症状；然而，它们无法阻止COPD的进展。相比之下，纳米颗粒（NPs）因其高特异性、生物相容性和更高的生物利用度，为治疗COPD提供了巨大的治疗潜力。此外，基于NP的药物递送系统给药频率较低且剂量较小，有助于将副作用降至最低。在这篇综述中，探讨了传统疗法的益处和局限性，同时深入洞察了基于NP的系统在COPD治疗中的先进应用。
